Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoshu Yu

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Infection and Drug Resistance|December 1, 2025
Fatal Mpox Coinfection in Advanced AIDS: A Case ReportYansi Lu, Xiaoshu Yu, Changjing Zhou, et al.
Toxics|May 27, 2026
Sodium Hypochlorite Pre-Oxidation as a Key Contributor to Trihalomethane Formation and Carcinogenic Risk: Evidence from Adjacent Water Treatment PlantsRongjie Shi, Ning Liu, Tao Lan, et al.
International Journal of STD & AIDS|April 8, 2026
Albuvirtide-based regimens for advanced- stage HIV and <i>Talaromyces marneffei</i> co-infection: A longitudinal case seriesXiaoshu Yu, Shengyi Li, Changjing Zhou, et al.
Frontiers in Pharmacology|October 13, 2022
Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosisZhiwen Jiang, Yinyi Wei, Weie Huang, et al.
Mycopathologia|February 5, 2025
Voriconazole Steady-State Trough Concentrations and Clinical Outcomes in Patients with TalaromycosisZhiwen Jiang, Cong Song, Bingkun Li, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Infection and Drug Resistance|December 1, 2025
Fatal Mpox Coinfection in Advanced AIDS: A Case ReportYansi Lu, Xiaoshu Yu, Changjing Zhou, et al.
Toxics|May 27, 2026
Sodium Hypochlorite Pre-Oxidation as a Key Contributor to Trihalomethane Formation and Carcinogenic Risk: Evidence from Adjacent Water Treatment PlantsRongjie Shi, Ning Liu, Tao Lan, et al.
International Journal of STD & AIDS|April 8, 2026
Albuvirtide-based regimens for advanced- stage HIV and <i>Talaromyces marneffei</i> co-infection: A longitudinal case seriesXiaoshu Yu, Shengyi Li, Changjing Zhou, et al.
Frontiers in Pharmacology|October 13, 2022
Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosisZhiwen Jiang, Yinyi Wei, Weie Huang, et al.
Mycopathologia|February 5, 2025
Voriconazole Steady-State Trough Concentrations and Clinical Outcomes in Patients with TalaromycosisZhiwen Jiang, Cong Song, Bingkun Li, et al.
Pageof 1